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Sensitivity of Urinary Mesothelin in Patients with Malignant
Mesothelioma
Jenette Creaney, PhD,*† Arthur W. Musk, MBBS, MD, FRACP,*‡§
and Bruce W. S. Robinson, MBBS, MD, FRACP*†‡
Introduction: Malignant mesothelioma (MM) is an aggressive,
uniformly fatal tumor usually caused by exposure to asbestos.
Soluble mesothelin has been intensively investigated in the serum
as a biomarker for this disease. As urine is less complex and less
invasive to collect than serum and may be a more acceptable
specimen for large-scale screening studies of asbestos-exposed
individuals, we determined whether the sensitivity and specificity
for MM could be improved by measuring soluble mesothelin in
the urine.
Methods: Soluble mesothelin concentrations were determined using
the MESOMARK™ assay in concurrent serum and urine samples
from 70 patients with pleural MM, 111 patients with asbestos-
related lung or pleural disease, and 45 patients with benign nonas-
bestos-related lung and pleural disease. Only patients with serum
creatinine levels within the normal range were included in the study.
Sensitivities were determined and receiver operator characteristic
curves were generated to compare the diagnostic accuracy of me-
sothelin in the serum and urine.
Results: At a specificity of 95% relative to individuals with benign
lung or pleural disease, serum mesothelin had a sensitivity of 66%
and area under the curve of 0.882, whereas urinary mesothelin
corrected for urine creatinine concentration had a sensitivity of 53%
and area under the curve of 0.787.
Conclusions: The sensitivity of urinary mesothelin does not warrant
the use of urine as a biomarker specimen for MM diagnosis.
Key Words: Mesothelioma, Mesothelin, SMRP, Diagnosis,
Biomarkers.
(J Thorac Oncol. 2010;5: 1461–1466)
Malignant mesothelioma (MM) is usually caused byexposure to asbestos and is an almost uniformly fatal
disease with most patients dying within 12 months of diag-
nosis.1,2 There is some evidence that radical surgical inter-
vention accompanied by chemotherapy and radiotherapy in
patients with early-stage disease may increase survival,3 al-
though selection bias could account for these observations.4
This possibility and the prospect of improved therapeutic
modalities for MM highlight the need for diagnosis of MM at
the earliest stage of disease occurrence.
Mesothelin has attracted attention as a potential diag-
nostic biomarker for MM. Serum soluble mesothelin is highly
specific for MM relative to healthy controls and patients with
benign pulmonary conditions, and has a sensitivity of 84% in
advanced disease.5 However, at diagnosis, sensitivity is re-
duced to 49%.6 Clearly, this level of sensitivity is not suffi-
cient for mesothelin to be considered as a stand-alone screen-
ing modality.
Urine is a more convenient biologic sample than serum
and is considerably less invasive to collect. Although not
generally accepted in routine patient management, numerous
research studies have analyzed urinary biomarker levels for
urogenetal cancers such as prostate7 and bladder.8 Recently, a
study by Badgwell et al.9 in patients with early-stage ovarian
cancer found that levels of mesothelin in the urine had
superior sensitivity for detecting disease than levels deter-
mined from corresponding serum samples. The authors found
that 42% of patients with early-stage ovarian cancer had
detectable levels of urine mesothelin compared with 12%
having a positive mesothelin serum assay. Furthermore, in
patients with advanced ovarian cancer, 75% had increased
mesothelin in their urine sample compared with 48% who had
increased serum mesothelin. Therefore, we examined patients
with MM to determine whether a similar pattern occurred.
Mesothelin has several soluble forms; a 31 kDa protein,
designated megakaryocyte potentiating factor derived from
the N-terminal sequence,10,11 and at least two C-terminal
derived proteins that will be designated “soluble mesothelin”
in this article. The predominant isoform of these soluble
mesothelin proteins produced by ovarian and MM cells is a
cleavage product of cell-bound mesothelin,12–14 the minor
form was identified as a product of alternative splicing of the
mesothelin gene and has a molecular weight between 42 and
45 kDa, designated soluble mesothelin-related protein.15
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The purpose of this study was to determine whether the
sensitivity and specificity for MM diagnosis can be improved
by measuring mesothelin concentrations in the urine.
PATIENTS AND METHODS
Patients and Controls
All samples were collected from patients presenting to
the respiratory clinics of either Sir Charles Gairdner Hospital
or the Hollywood Specialist Centre in Perth, Western Aus-
tralia. This study was approved by the human research ethics
committees of Sir Charles Gairdner and Hollywood Hospi-
tals, and all patients provided written informed consent. The
samples form part of the Australian Mesothelioma Tissue
Bank, a member back of the Australasian Biospecimen Net-
work, which is supported in part by the Australian National
Health and Medical Research Council. The final diagnosis in
all patients was confirmed by pathologists experienced in the
diagnosis of MM, lung cancer, and effusion cytology. The
diagnosis of pleural plaques, asbestosis, idiopathic pulmonary
fibrosis, and sarcoidosis was made in each case based on
accepted radiologic and clinical criteria.16–18 Clinical fol-
low-up of all cases was until death or for an average of 7
months (range, 1–42 months) to confirm that the clinical
pattern matched the diagnosis.
Blood samples were collected by routine venepuncture
and allowed to clot for at least 2 hours at room temperature,
or at 4°C overnight before processing. The urine samples
were collected at the same visit as the serum samples.
Patients were not dietarily restricted before sample collection.
Samples, blood and urine, were centrifuged at 1200g for 10
minutes, then the supernatant was removed, aliquoted, and
stored at 80°C until assayed.
Mesothelin
Soluble mesothelin concentrations were determined in
duplicate following the manufacturer’s instructions using a
double-determinant enzyme-linked immunosorbent assay
(MESOMARK kit; Fujirebio Diagnostics Incorporated,
Malvern, PA). Mesothelin concentrations were determined
from a standard curve performed on each plate and expressed
as nanometer. All assays were performed on coded samples
by technical staff unaware of the patients’ diagnoses. The
manufacturer’s reported assay sensitivity was 0.3 nM. For the
purposes of data analysis, concentrations of samples less than
0.3 were assigned a value of 0.03 nM.
Creatinine Assay and Estimated Glomerular
Filtration Rate
Serum and urinary creatinine concentrations were de-
termined by staff at the PathWest Laboratory (Queen Eliza-
beth II Medical Centre, Perth, Western Australia) using the
Jaffe Creatinine reagent (Roche, Castlehill, Australia) and
measured on the Roche Modular P Analyser and Roche
Hitachi 917 Analyser, respectively. The normal range for
serum creatinine was 45–90 mol/L for women and 60–110
mol/L for men. Only patients with creatinine levels within
the normal range were included in this study. The estimated
glomerular filtration rate (eGFR) was calculated using the
formula proposed by the modification of diet in renal disease
study group19: i.e., eGFR  32,788  serum creatinine1.154
 age0.203  (0.742 if female).
Western Immunoblotting
Western immunoblotting was performed as described
by Creaney et al.20 Urine was diluted 1:2 in standard reducing
buffer and separated by sodium dodecyl sulfate-polyacrylam-
ide gel electrophoresis. Protein was transferred to nitrocellu-
lose membrane, blocked in 10% skim milk powder, and
incubated with antimesothelin antibody (Clone MN; Rock-
land, Gilbertsville, PA) diluted 1:1000. As a control, cell
lysate of the human mesothelioma cell line JU77 established
in our laboratory21 was analyzed in parallel. This cell line had
been deposited in CellBank Australia (Westmead, NSW), and
it found to be free of contamination and confirmed to be
unique through short-tandem repeat profiling.
Statistical Analysis
Biomarker values were transformed to the log scale so
that distributions were closer to normality. For the same
reason, median biomarker values were estimated from the
mean on the log scale and exponentiated to provide the
estimate of the median on the original scale. For analyses that
required sample normalization and/or standardization, sam-
ples with mesothelin concentrations below the limit of detec-
tion (0.3 nM) were excluded. Differences between groups of
patients were assessed on transformed data by Student t test.
All reported p values are two sided. A level of p less than 0.05
was accepted as significant. Receiver operating characteristic
(ROC) curves display the trade-off between sensitivity and
specificity for biomarkers differentiating between groups of
patients. Area under the curve (AUC) was compared using
the method described by DeLong et al.,22 which accounts for
the correlation due to the markers being measured on the
same set of serum samples. Pearson’s correlation coefficient
was used to assess correlations between serum and urinary
measures (log scale). Statistical analysis was performed using
the PASW version 18 statistics package (SPSS Inc., Chicago,
IL) and MedCalc Version 11 (MedCalc Software, Belgium).
RESULTS
Patient Characteristics
Serum and matching urine samples were collected from
70 patients with pleural MM. The majority of cases (77%) were
of predominantly epithelioid histology or from patients in whom
a diagnosis was made on immunocytological grounds.23 Sera
and urine were collected from 111 people with benign asbestos-
related diseases (39 patients with asbestosis with or without
concomitant pleural plaques and 72 patients with pleural plaques
only). Samples were also collected from 19 patients with idio-
pathic pulmonary fibrosis, 19 people with sarcoidosis, seven
people with nonmalignant exudative effusions and from 20
patients with lung cancer. Groups were age and sex matched,
except for the lung cancer group that had significantly older
people than those in the MM group and also the benign nonas-
bestos-exposed control group that had significantly more fe-
males than that in the MM group (Table 1).
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Mesothelin Levels in Serum
Serummesothelin levels in patients withMM ranged from
below the limit of detection to 70 nM (Figure 1A). Levels were
significantly higher in the serum of patients with MM than the
patients with benign asbestos-related diseases (p  0.0001),
patients with other benign lung and pleural disease (p 0.0001),
and patients with lung cancer (p  0.0001) (Table 1). Using a
cutoff of 2.5 nM, 47% of patients with MM were mesothelin
positive, all other individuals in this study had mesothelin levels
below 2.5 nM, except for two patients with lung cancer, one
FIGURE 1. Serum and urinary mesothelin
concentration in patients with malignant me-
sothelioma and controls. A, Soluble mesothelin
concentrations were determined in the serum,
and individual patient values are plotted on
the graph. Mesothelin levels were plotted for
all individuals with asbestosis and pleural
plaques (asb. and plaques), pleural plaques
(plaques), idiopathic pulmonary fibrosis, sar-
coidosis, benign pleural effusions, lung can-
cer, and malignant mesothelioma (MM) (re-
gardless of the histology). B, Receiver
operator characteristic (ROC) curves for se-
rum mesothelin to differentiate between pa-
tients with MM (n  70) and the patients
with benign lung and pulmonary disease
(n  156). C, Mesothelin concentrations
were determined in the urine sample for the
above patient groups. For those individuals
with measurable urinary mesothelin, concen-
trations were normalized to urinary creati-
nine concentration. D, ROC curve for urinary
mesothelin standardized to urinary creatinine
to differentiate between patients with MM
(n  44) and the patients with benign lung
and pulmonary disease (n  22). benign
lung and pulmonary conditions;  malignant
conditions).
TABLE 1. Patient Characteristics and Mesothelin Concentrations in Serum and Urine
No. of
Cases
(Female)
Age
Mean
(Range)
Serum
Mesothelind,e
(nM)
No. of Positive
Serum
Samplesf
No. of Negative
Urinary
Samplesg
Urinary Mesothelin:
Urinary Creatinine
Ratiod,e (101)
MM 70 (8F) 68 (44–94) 2.68  0.15 33/70 26/70 2.27  0.17
Epithelial 54 (7F) 68 (44–94) 2.78  0.17 27/54 20/54 2.15  0.2
Biphasic 10 (0F) 70 (46–88) 3.53  0.37 5/10 3/10 3.16  0.5
Sarcomatoid 6 (1F) 70 (66–78) 1.21  0.18 1/6 3/6 2.01  0.37
Benign asbestos related disease controls 111 (8F)ns 69 (40–89)ns 0.45  0.12c 0/111 96/111 0.52  0.14c
Asbestosis  Plaques 39 (3F) 71 (40–89) 0.45  0.22c 0/39 32/39 0.54  0.14b
Plaques 72 (5F) 68 (48–88) 0.46  0.15c 0/72 64/72 0.51  0.24c
Benign non-asbestos exposed controls 45 (17F)c 64 (24–88)ns 0.35  0.22c 0/45 38/45 0.7  0.25c
IPF 19 (4F) 68 (42–88) 0.5  0.36c 0/19 15/19 0.99  0.37ns
Sarcoidosis 19 (12F) 61 (24–83) 0.27  0.32c 0/19 17/19 0.48  0.17ns
PE—Exudate 7 (1F) 65 (33–77) 0.28  0.61c 0/7 6/7 0.37
Lung cancer 20 (3F)ns 75 (40–85)a 0.71  0.33c 2/20 11/20 0.85  0.25a
a p  0.05.
b p  0.001.
c p  0.0001.
d Exponentiated mean of log transformed data  standard error.
e Significant difference between indicated groups and the MM group as a whole (n  70) as determined by Student t test on log-transformed data.
f The number of samples with serum mesothelin more than 2.5 nM.
g The number of samples with urinary mesothelin below the limit of detection of the assay.
MM, malignant mesothelioma; IPF, idiopathic pulmonary fibrosis; PE, pleural effusion; ns, not significant.
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with squamous cell carcinoma and one with poorly differenti-
ated adenocarcinoma of the lung.
When ROC curves were generated to assess the ability
of serum mesothelin to distinguish patients with MM from
patients with benign asbestos-related disease, the AUC was
0.882 (95% CI, 0.826–0.925). Curves generated to distin-
guish patients with MM from all patients with benign disease
had an AUC of 0.881 (95% CI, 0.832–0.920) (Figure 1B). In
this study, at a specificity of 95%, serum mesothelin had a
sensitivity of 67%, at a cutoff value of 1.62 nM.
To assess the influence of kidney function on the
diagnostic performance of mesothelin, individual’s serum
mesothelin levels were divided by their eGFR. The AUC of
the ROC curve to distinguish patients with MM from patients
with benign conditions using serum mesothelin normalized
for eGFR was 0.831 (95% CI, 0.71–0.881), which was not
significantly different from the AUC of non-normalized se-
rum mesothelin (Table 2). There was no correlation between
serum mesothelin and serum creatinine (data not shown).
Mesothelin Levels in Urine
Mesothelin levels in the urine sample of patients with
MM ranged from undetectable to 38 nM. In approximately
37% of patients with MM and 82% of nonmesothelioma
patients, urinary mesothelin was below the limit of detection
(Table 1). An ROC curve, using a value of 0.03 nM for
samples below the limit of detection, was generated to assess
the ability of urinary mesothelin to distinguish patients with
MM from patients with benign conditions. The curve had an
AUC of 0.548 (95% CI, 0.480–0.0614), not significantly
different from the reference, demonstrating that urinary me-
sothelin had no discriminatory value in this setting (Table 2).
As variation in volume of urine can affect the concentration
of proteins, for those samples with measurable mesothelin,
urinary mesothelin concentrations were standardized against
urinary creatinine concentrations (Figure 1C). In this subset
of cases, standardized urinary mesothelin levels were signif-
icantly higher in the patients with MM than the patients with
benign asbestos-related diseases (p  0.0001), patients with
other nonmalignant pulmonary conditions (p  0.0001), and
lung cancer (Table 1). The AUC after ROC analysis for
urinary mesothelin normalized to urinary creatinine concen-
trations to distinguish patients with MM from the patients
with benign disease was 0.870 (95% CI, 0.764–0.940) (Fig-
ure 1D), there was no significant difference in the AUC when
serum mesothelin or standardized urinary mesothelin was
used as the biomarker (Table 2). At a specificity of 95%,
urinary mesothelin levels (corrected for urine creatinine con-
centrations) had a sensitivity of 60%.
Correlation of Serum and Urine Mesothelin
Concentrations
Mesothelin was not measurable in the urine sample of
26 patients with MM; however, mesothelin was quantifiable
in the matching serum sample in all except one of these cases
(Figure 2A). Similarly, urinary mesothelin was not deter-
mined in 134 individuals with benign lung and pulmonary
conditions, although mesothelin was quantifiable in the
matching serum sample in 109 (i.e., 80%) of these cases
(Figure 2C). In four of the 47 patients with benign conditions
with serum mesothelin levels below the limit of detection,
mesothelin was quantitated in the urine (Figure 2C).
A significant correlation was observed between serum
and absolute urinary mesothelin (Pearson r2  0.515; p 
0.0001) and standardized urinary mesothelin to urinary cre-
atinine concentrations (r2 0.743; p 0.0001; Figure 2B) in
patient with MM. No correlation was observed between
serum and urinary mesothelin levels in patients with benign
conditions (Figure 2D).
Full-Length Mesothelin is Detectable in Urine
To determine whether the product measured in the
enzyme-linked immunosorbent assay was full-length intact
mesothelin or a breakdown product, urine samples were
analyzed by Western immunoblotting. A major band of
approximately 40 kDa that reacted with an antimesothelin
antibody was detected in urine sample from a patient with
MM (Figure 3). Only in urine samples with greater than
approximately 20 nM of mesothelin were protein bands
detectable by Western immunoblotting (data not shown).
DISCUSSION
Soluble mesothelin was detectable in the urine sample
of patients with MM and patients with benign disease with
normal renal function. However, in matching samples, me-
sothelin could be quantitated in a greater number of serum
TABLE 2. Area under the ROC Curve for Biomarkers Discriminating All Patients with MM
(n  70) from Benign Controls (n  156)
Biomarker
No. of Cases
AUCb SEc
Asymptotic 95% CI
MM Benign Lower Bound Upper Bound
Serum mesothelin 70 156 0.881 0.026 0.832 0.920
Serum mesothelin: eGFR 69 127 0.831ns 0.029 0.791 0.881
Urinary mesothelin 70 156 0.548a 0.045 0.480 0.614
Urinary mesothelin:urinary creatinine 44 22 0.870ns 0.044 0.764 0.940
a p  0.001.
b Significant difference between indicated AUC and the AUC for serum mesothelin, determined by pairwise comparison.
c Standard error under the nonparametric assumption.
AUC, area under the curve; ROC, Receiver operating characteristic; eGFR, estimated glomerular filtration rate; SE, standard error, CI,
confidence interval; ns, not significant.
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rather than urine samples. The diagnostic accuracy of soluble
mesothelin for MM was similar when serum or urine was
used as a sample. This is different from the observation that
urine mesothelin had a greater sensitivity for early-stage
ovarian cancer patients than serum mesothelin,9 and one
possibility is that different biologic processes underlie the
generation of detectable mesothelin in these two conditions.
In the study by Badgwell et al.,9 urine mesothelin
concentrations were corrected for renal function as estimated
by the GFR (Cockcroft-Gault equation). The GFR calculation
included patient age, weight, and sex. As data were not
presented that showed serum mesothelin level adjusted by
eGFR, it is not possible to determine whether it is the
incorporation of these factors into the analysis that improved
the sensitivity of the assay. In this study, only patients with
serum creatinine within the normal range were included, and
no increase in sensitivity was observed in serum or urinary
mesothelin when the results were normalized to eGFR.
Recently, it has been suggested that renal function
should be accounted for when interpreting soluble mesothelin
levels in the serum.24,25 Hollevoet et al. demonstrated a
correlation between renal function and serum mesothelin,
which was similar to our observations in an independent
study (manuscript in preparation). Therefore, poor renal func-
tion results in increased levels of serum mesothelin and
increases the number of false-positive results for the diagno-
sis of malignancy. As all the participants of this study had
normal creatinine levels, no correlation between serum me-
sothelin and estimated renal function was observed.
Decreased renal function may also be associated with
increased urinary protein. Although soluble mesothelin was
not detected in the urine sample of all study participants, we
did observe full-length intact mesothelin protein in the urine
sample of people with normal renal function; therefore,
additional factors may account for the presence of mesothelin
in the urine. This could simply be a reflection of the increased
mesothelin protein burden produced by the tumor being too
great to be filtered completely by the kidneys as evidenced by
the correlation between serum and urinary mesothelin levels
in patients with MM. However, in the patients with other
asbestos-related diseases or other benign conditions, the dy-
namic range of serum mesothelin was not as great and no
correlation could be observed between serum and urinary
mesothelin. Indeed, the patient in this group with the highest
serum mesothelin had no protein measurable in the urine. It is
possible that mesothelin in the glomerular filtrate is reab-
FIGURE 2. Bivalent scatter plots, cor-
relating serum mesothelin with (A and
C) urinary mesothelin, and (B and D)
urinary mesothelin corrected for uri-
nary creatinine concentration, for (A
and B) patients with MM and (C and
D) patients with benign lung and pul-
monary conditions. MM, malignant
mesothelioma.
FIGURE 3. Sample of urine from a patient with MM with a
urinary mesothelin concentration of 37 nM analyzed by
Western immunoblotting using an antibody against me-
sothelin. As a comparison, mesothelin was detected in a
lysate of JU77, a human MM cell line. Molecular weights
are indicated on the left of the gel. MM, malignant
mesothelioma.
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sorbed by the kidney, degraded in the urine sample or bound
in the serum by other factors including possibly CA125.26
Although urinary measures maybe a less intrusive
means of assaying biomarkers, the diagnostic accuracy of
serum mesothelin and the greater number of individuals with
detectable serum mesothelin mean that the use of a urine-
based screening assay as has been suggested for the large-
scale screening of asbestos-exposed communities is not sup-
ported by the results of this study. However, the question
remains about the value of screening using serum mesothelin.
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